The identification of a previously unrecognized APC/PTPN13/STAT1-dependent tumor immune-suppressive mechanism in this study represents a significant advance, offering a compelling strategy for development of therapeutic interventions for CRC. This evidence concerns the gene STAT1 and colorectal carcinoma.